Development of Synthetic Platforms for the In Vitro Glycosylation of Proteins
N-linked glycans play a role in protein stability, solubility and cell trafficking as well as cell signaling. Therefore, the glycosylation of proteins is one important parameter in the optimization of animal cell culture-derived drugs including monoclonal antibodies, growth factors, and hormones. Over the past years efforts have been made to modify and implement the N-glycosylation machinery in yeast and E. coli, respectively, for the production of biologics with human-type glycoforms. An alternative approach is the in vitro glycoengineering of proteins by synthesizing and modifying the glycostructure via cell-free biocatalytic processes using purified enzymes and nucleotide sugars. Case studies have shown very promising results in terms of increasing the level of galactosylation and sialylation on IgG. In order to in vitro glycosylate proteins, lipid-linked oligosaccharides (LLO) and nucleotide sugars are needed. Challenges associated with their biocatalytic synthesis are, in particular, the expression and the purification of membrane-associated glycosyltransferases, and the provision of expensive sugar nucleotides as building blocks.
Aim of the project
Aim of the project is to develop a cell-free synthetic platform for the efficient synthesis of lipid-linked oligosaccharides for the in vitro glycosylation of proteins. Genes of enzymes used as biocatalysts are expressed in